About National Cancer Center

font size| large | normal | small |

About Research Institute

Director's message
Each Division

Division of Molecular Pathology

Division of Genetics

Division of Familial Cancer Research

Division of Multistep Carcinogenesis

Division of Virology

Division of Cancer Development System

Group for Cancer Development and Progression

>>

Division of Metastasis and Invasion Signaling

Division of Molecular and Cellular Medicine

Division of Cancer Biology

Division of Cancer Differentiation

Division of Hematological Malignancy

Group for Research of Molecular Functions and Targets

>>

Division of Pharmacogenomics

Division of Pharmacoproteomics

Division of Epigenomics

Division of Genome Biology

Division of Cancer Genomics

Group for Development of Molecular diagnostics and Individualized Therapy

>>

Division of Cancer Pathophysiology

Division of Cancer Stem Cell

Division of Gene and Immune Medicine

Division of Genome Stability Research

Division of Chemotherapy and Clinical Research

Group for Translational Research

>>

Central Animal Division

Central Radioisotope Division

Core Facility Division

Core Facilities for Research and Innovative Medicine

>>

Division of Refractory Cancer Research

Division of Cancer Prevention Research

Division of Integrative Omics and Bioinformatics

Division of Brain Tumor Translational Research

Project Group

>>
For Visitors
Publication & Reports

List of Papers Published in This Month

Cumulated List of Papers Published in This Year

Annual Reports
Positions & Fellowships

HOME > National Cancer Center Research Institute > Each Division > Division of Pharmacoproteomics > Biomarker for Personalized Medicine > Biomarker for Personalized Medicine

Biomarker for Personalized Medicine

The project established the collaboration with medical doctors and researchers in the hospitals including the National Cancer Center Hospital, industrial companies, universities and public institutes. Our goal is to contribute to the improvement of cancer therapy using the results of cancer proteomics. The collaborations between various fields at an early phase should be essential for successful clinical applications.

to this page top